Trial | NCT01379677  Report issue

Title

Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison
Diagnosis of Coronary Artery Disease With Rubidium-82 PET and Technetium-99m-MIBI SPET: A Head to Head Comparison, Versus Coronary CT Angiography

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    135
The main purpose of this study is to compare myocardial perfusion imaging using Rubidium-82 PET with Tc-99m-MIBI SPET, in the evaluation of significant Coronary Artery Disease (CAD).
Study Started
Feb 28
2011
Primary Completion
Nov 30
2013
Study Completion
Nov 30
2013
Last Update
May 14
2014
Estimate

Drug Rubidium-82

Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use

  • Other names: CardioGen-82

Drug Sestamibi. reconstitution with sodium pertechnetate (99mTc)

Maximum dose allowed per injection: 1000 MBq Intravenous Use

  • Other names: Technescan MIBI

Single arm Other

This is an Head to Head Comparison between Rubidium-82 PET and Tc-99m-MIBI SPET with CTA as gold standard. All the patients will undergo the three imaging protocols.

Criteria 

Inclusion Criteria:

Referred for scintigraphy to assess myocardial ischaemia
Ability to give informed written consent.

Exclusion Criteria:

Impaired capacity to consent
Pregnancy, or breastfeeding
Allergy to iv contrast
Renal failure
Severe Uncontrolled asthma
Claustrophobia
No Results Posted